153 related articles for article (PubMed ID: 38712400)
1. Molecule engineering strategy of toll-like receptor 7/8 agonists designed for potentiating immune stimuli activation.
Gu L; Kong X; Li M; Chen R; Xu K; Li G; Qin Y; Wu L
Chem Commun (Camb); 2024 May; 60(42):5474-5485. PubMed ID: 38712400
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses.
Nuhn L; De Koker S; Van Lint S; Zhong Z; Catani JP; Combes F; Deswarte K; Li Y; Lambrecht BN; Lienenklaus S; Sanders NN; David SA; Tavernier J; De Geest BG
Adv Mater; 2018 Nov; 30(45):e1803397. PubMed ID: 30276880
[TBL] [Abstract][Full Text] [Related]
3. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
Lee SN; Jin SM; Shin HS; Lim YT
Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
[TBL] [Abstract][Full Text] [Related]
4. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
Smits EL; Ponsaerts P; Berneman ZN; Van Tendeloo VF
Oncologist; 2008 Aug; 13(8):859-75. PubMed ID: 18701762
[TBL] [Abstract][Full Text] [Related]
5. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
6. Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy.
Varshney D; Qiu SY; Graf TP; McHugh KJ
AAPS J; 2021 Jun; 23(4):90. PubMed ID: 34181117
[TBL] [Abstract][Full Text] [Related]
7. Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014 - 2020.
Kieffer ME; Patel AM; Hollingsworth SA; Seganish WM
Expert Opin Ther Pat; 2020 Nov; 30(11):825-845. PubMed ID: 33052748
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
9. Toll-Like Receptors 7/8: A Paradigm for the Manipulation of Immunologic Reactions for Immunotherapy.
Li F; Song B; Zhou WF; Chu LJ
Viral Immunol; 2023 Nov; 36(9):564-578. PubMed ID: 37751284
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
11. In vivo cancer vaccination: Which dendritic cells to target and how?
Chiang CL; Kandalaft LE
Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
[TBL] [Abstract][Full Text] [Related]
12. Latest Advances in Small Molecule TLR 7/8 Agonist Drug Research.
McGowan DC
Curr Top Med Chem; 2019; 19(24):2228-2238. PubMed ID: 31769363
[TBL] [Abstract][Full Text] [Related]
13. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques.
Moody MA; Santra S; Vandergrift NA; Sutherland LL; Gurley TC; Drinker MS; Allen AA; Xia SM; Meyerhoff RR; Parks R; Lloyd KE; Easterhoff D; Alam SM; Liao HX; Ward BM; Ferrari G; Montefiori DC; Tomaras GD; Seder RA; Letvin NL; Haynes BF
J Virol; 2014 Mar; 88(6):3329-39. PubMed ID: 24390332
[TBL] [Abstract][Full Text] [Related]
15. Bioorthogonal Activation of TLR7 Agonists Provokes Innate Immunity to Reinforce Aptamer-Based Checkpoint Blockade.
Wei Y; Qin G; Wang Z; Zhao C; Ren J; Qu X
ACS Nano; 2023 Mar; 17(6):5808-5820. PubMed ID: 36916491
[TBL] [Abstract][Full Text] [Related]
16. Decreased dengue replication and an increased anti-viral humoral response with the use of combined Toll-like receptor 3 and 7/8 agonists in macaques.
Sariol CA; Martínez MI; Rivera F; Rodríguez IV; Pantoja P; Abel K; Arana T; Giavedoni L; Hodara V; White LJ; Angleró YI; Montaner LJ; Kraiselburd EN
PLoS One; 2011 Apr; 6(4):e19323. PubMed ID: 21559444
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of innate immune cells by light-activated TLR7/8 agonists.
Ryu KA; Stutts L; Tom JK; Mancini RJ; Esser-Kahn AP
J Am Chem Soc; 2014 Aug; 136(31):10823-5. PubMed ID: 25029205
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
19. Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists.
Wynn JL; Scumpia PO; Winfield RD; Delano MJ; Kelly-Scumpia K; Barker T; Ungaro R; Levy O; Moldawer LL
Blood; 2008 Sep; 112(5):1750-8. PubMed ID: 18591384
[TBL] [Abstract][Full Text] [Related]
20. Engineering Therapeutic Strategies in Cancer Immunotherapy via Exogenous Delivery of Toll-like Receptor Agonists.
Jeong S; Choi Y; Kim K
Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
